Pasture Holdings Ltd.
2 Corporation Road #03-04/05
Corporation Place S618494
Singapore

FOR IMMEDIATE RELEASE

PASTURE GROUP EXTENDS ITS REGULATED HANDLING CAPABILITY INTO ANIMAL HEALTH WITH AVS VETERINARY BIOLOGICS LICENCE

- Pasture PharmaHub Pte. Ltd. has been granted a licence to possess veterinary biologics for commercial purposes.

- The licence allows Pasture to import veterinary vaccines into Singapore, extending the Group's regulated handling capability, built on its existing HSA pharmaceutical licences, into animal health.

Singapore, 23 October 2026 – Pasture Holdings Ltd. ("**Pasture**" and together with its subsidiaries, the "**Group**"), is pleased to announce that its wholly owned subsidiary, Pasture PharmaHub Pte. Ltd. ("**PHB**"), has been granted the licence to possess veterinary biologics for commercial purposes by the Animal & Veterinary Service ("**AVS**"). It is a prerequisite for importing veterinary vaccines into Singapore.

The Group holds Health Sciences Authority ("**HSA**") licences to import pharmaceuticals. PHB also holds HSA Poison A licence, which covers the wholesale of veterinary medicines. This AVS licence adds veterinary biologics to the regulated products the Group is licensed to handle.

Outlook

This licence gives Pasture a regulated entry point into veterinary vaccines, a market driven largely by farm animals. Global veterinary vaccine sales were around US$9.5 billion in 2022, with livestock, pigs and poultry accounting for around three-quarters of that total, and is forecasted to be US$11.4 billion in 2026[1].

Closer to home, livestock accounts for around 15% of Southeast Asia's agricultural gross domestic product, and vaccination is a key tool against transboundary diseases such as foot-and-mouth disease and classical swine fever[2]. The Food and Agriculture Organization ("**FAO**") of the United Nations estimates that foot-and-mouth disease alone costs around US$21 billion a year globally in direct production losses and vaccination[3].

---

[1] BIS Research, via Statista (2024), 'Global veterinary vaccine market share by animal type'. Figures for 2022 are actuals; livestock, porcine and poultry combined = US$7.13bn of US$9.45bn. 2026 figure (US$11.42bn) is a BIS Research forecast. https://www.statista.com/statistics/944331/veterinary-vaccine-market-share-by-animal-type-worldwide/

[2] Mai T.N. et al. (2024), 'Transboundary viral diseases of pigs, poultry and ruminants in Southeast Asia: a systematic review', Veterinary Quarterly, 44(1). https://www.tandfonline.com/doi/full/10.1080/01652176.2024.2397796#abstract. The 15% figure is cited in the review from WOAH (2021).

[3] FAO (2025), 'Combating livestock diseases: A global challenge'. https://www.fao.org/animal-health/news-events/news/detail/combating-livestock-diseases--a-global-challenge/en

Pasture Holdings Ltd.
2 Corporation Road #03-04/05
Corporation Place S618494
Singapore

With the licence in place, Pasture is now pursuing opportunities to supply veterinary biologics within its scope. The licence allows the Group to import specified vaccines into Singapore for re-export. The Group can now act as a licensed hub between vaccine manufacturers and buyers in overseas markets. For Pasture, which already serves customers in over 50 countries, this is a potential new revenue stream. More vaccines can be added to the licence over time.

About the regulatory body

AVS is a cluster of the National Parks Board[4], a statutory board constituted under the National Parks Board Act (Cap. 198A) and is Singapore's main point of contact on animal and veterinary matters.

Mr Lloyd Soong, Executive Chairman and Chief Executive Officer of Pasture Holdings, said:

"Handling biological products carries a responsibility to our staff and the wider community. This licence reflects the standards we hold ourselves to, and it opens a new area for us to explore within animal health."

##

[4] https://www.nparks.gov.sg/

Pasture Holdings Ltd.
2 Corporation Road #03-04/05
Corporation Place S618494
Singapore

About Pasture Holdings Ltd.

Pasture is a Singapore-based, SGX Catalist-listed pharmaceutical and medical supplies group, supplying over 2,000 third-party pharmaceutical products and medical supplies to customers in over 50 countries. Its wholesale and drop-shipment business includes cold-chain management for temperature-sensitive pharmaceutical products, a segment that has grown globally from US$272 billion in biopharma cold chain product sales in 2016 to US$440 billion in 2024 – a compound annual growth rate of approximately 6.2%[1].

Beyond wholesale distribution, Pasture develops and sells its own proprietary range of masks under the Pasture Masks brand, and in close collaboration with a manufacturing partner supplies Hart-S, a sildenafil oral dissolving strip product. The Group is progressing plans to expand its oral dissolving strip technology into supplements and additional molecules. Pasture also operates furlife, a pet health platform, with customers in Singapore, Japan, Canada, and the United States.

For more information, please visit https://pasturegroup.com/

[1] Statista, Global biopharma cold chain product sales from 2016 to 2024. https://www.statista.com/statistics/303081/trend-in-biopharma-cold-chain-products-global-sales/

For media enquiries, please contact
Corporate Communications & Digital Marketing Manager
Claire Soong
Email: contact@pasturegroup.com
Tel: +65 6515 6516

This press release and its contents have been reviewed by the Company's sponsor, SAC Capital Private Limited (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Lee Khai Yinn (Tel:(65) 6232 3210) at 1 Robinson Road, #21-01 AIA Tower, Singapore 048542.